rs1154155 — TRA

Your T-Cell Receptor and the Autoimmune Root of Narcolepsy

Narcolepsy type 1 — the form marked by sudden muscle weakness (cataplexy) and daytime sleep attacks — is not simply a sleep disorder. It is an autoimmune disease where the immune system destroys a small cluster of neurons in the hypothalamus that produce hypocretin¹¹ hypocretin
also called orexin; a neuropeptide that stabilizes the switch between waking and sleep states. Once lost, these roughly 70,000 neurons do not regenerate, and the wakefulness-sleep boundary becomes unstable for life. The genetic variant rs1154155 sits inside the T-cell receptor alpha (TRA) locus — the gene region that encodes the alpha chain of the T-cell receptor, the molecule T cells use to recognize peptides presented by HLA class II molecules.

The Mechanism

The TRA locus spans a large stretch of chromosome 14q11.2 and contains approximately 70 J-segment genes that are somatically recombined during T-cell development to generate diverse receptor specificities. rs1154155 falls within an 18-kb region encompassing J-segment genes TRAJ24 and TRAJ28. It is in near-perfect linkage disequilibrium with a functional coding variant (rs1483979) that encodes a leucine-to-phenylalanine substitution in the complementarity-determining region 3 (CDR3) of the TRAJ24 segment — the very region that contacts the peptide-HLA complex directly.

The leading biological model is that specific TRA chain sequences encoded near the G-risk haplotype generate T-cell receptors with higher affinity for hypothalamic peptides presented by HLA-DQB1*06:02²² HLA-DQB1*06:02
the HLA allele present in >95% of narcolepsy type 1 patients. When the immune system encounters a cross-reactive antigen — most likely a peptide from influenza H1N1 hemagglutinin or related pathogens — these high-affinity T cells mount an immune response that simultaneously targets hypocretin neurons. The 2009–2010 H1N1 pandemic and the AS03-adjuvanted Pandemrix vaccine both dramatically elevated narcolepsy incidence in children carrying HLA-DQB1*06:02 and TRA risk genotypes, providing the strongest epidemiological confirmation of this autoimmune trigger model.

The Evidence

The discovery study by Hallmayer et al.³³ Hallmayer et al.
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature Genetics, 2009 genotyped 1,830 narcolepsy cases and 2,164 controls across European, Asian, and African-American populations. rs1154155 showed the strongest signal (p < 10⁻²¹) with an average allelic odds ratio of 1.69. Genotypic odds ratios were 1.94 for heterozygotes (GT) and 2.55 for homozygotes (GG) relative to TT — a classic additive dose-response pattern. This was the first documented association between the TRA locus and any human disease.

Ollila et al.⁴⁴ Ollila et al.
Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. Nature Communications, 2023 expanded this to 6,073 cases and 84,856 controls, confirming the TRA signal and mechanistically linking rs1154155 to altered TRAJ24 and TRAJ28 chain usage in T-cell repertoire sequencing data (posterior probability 0.958 for the TRAJ28 co-localization signal).

A Chinese case-control study (Ouyang et al. 2020⁵⁵ Ouyang et al. 2020, 903 cases, 1,981 controls) found that among HLA-DQB1*06:02-positive individuals, carrying GG or GT genotypes conferred an OR of 9.33 compared to TT (p = .017), illustrating how HLA and TRA risk genotypes multiply each other's effect. In HLA-negative individuals, the TRA association was not statistically significant — confirming that TRA genotype modifies rather than independently causes narcolepsy risk.

Practical Actions

The absolute risk of developing narcolepsy remains low even in those carrying both HLA-DQB1*06:02 and the TRA G-risk genotype (lifetime prevalence is approximately 1 in 2,000). The clinical value of knowing this genotype lies in:

• Earlier recognition: Symptom clusters (excessive daytime sleepiness, sleep paralysis, hypnagogic hallucinations, cataplexy) often precede diagnosis by 5–10 years. Carriers with emerging symptoms should seek polysomnography and hypocretin CSF measurement promptly rather than attributing symptoms to lifestyle.
• Infection and vaccination vigilance: G-risk carriers — especially those known to be HLA-DQB1*06:02 positive — should discuss vaccine timing and neurological symptoms with their physician when novel H1N1-type antigens are in circulation.
• Sleep architecture monitoring: Narcolepsy type 1 disrupts REM sleep regulation distinctively. Sleep studies (overnight polysomnography + MSLT) are the diagnostic standard and can detect REM-onset abnormalities before full symptom development.

Interactions

The TRA locus does not act alone. Narcolepsy type 1 requires HLA-DQB1*06:02 as the essential prerequisite — present in >95% of cases. rs1154155 TRA risk genotypes interact multiplicatively with HLA-DQB1*06:02 status: the OR for narcolepsy among HLA-positive individuals carrying GG or GT genotypes is dramatically higher (OR ~9.33) than in the overall population. Separately, the TCR beta locus variant rs9648789 (TRB locus) also associates with narcolepsy and may compound with TRA risk genotypes, since both alpha and beta chains must heterodimerize to form the functional TCR that recognizes peptide-HLA complexes. The precise combined effect of rs1154155 + rs9648789 has not been quantified in a single study, but pathway logic suggests additive or super-additive risk among carriers of both loci.